Six treatment-resistant schizophrenic patients were given a ten-week single-blind trial of carbamazepine. Treatment resistance was determined on the basis of documented failure to respond to treatment with at least three neuroleptic drugs from two different chemical classes. The adjunctive use of carbamazepine resulted in a significant improvement of the negative symptoms of schizophrenia. These symptoms are often poorly responsive to conventional antipsychotic drugs. Therefore, controlled studies should be performed to further assess the possible efficacy of carbamazepine in schizophrenia.
BallengerJC, PostRM. Carbamazepine in manic-depressive illness: a new treatment.Am J Psychiatry1980; 137: 782–90.
2.
OkumaT. Therapeutic and prophylactic effects of carbamazepine in bipolar disorders.Psychiatr Clin North Am1983; 6: 1–4.
3.
PostRW, UhdeTW. Carbamazepine in bipolar illness.Psychopharmacol Bull1985; 21: 10–7.
4.
NolenWA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder.Acta Psychiatr Scand1983; 67: 218–25.
5.
HakolaHPA, LaulumaaVAO. Carbamazepine in treatment of violent schizophrenics (letter).Lancet1982; 1: 1358.
6.
NeppeVM. Carbamazepine in the psychiatric patient (letter).Lancet1982; 1: 1358.
7.
LuchinsDJ. Effects of carbamazepine in aggressive behavior: an open study (abstract). Presented at the annual meeting, American College of Neuropsychopharmacology, Puerto Rico, Dec. 16, 1983.
8.
KleinE, BentolE, LererB, BelmakerR. Carbamazepine and haloperidol v. placebo and haloperidol in excited psychoses.Arch Gen Psychiatry1984; 41: 165–70.
9.
JohnstoneEC, CrowTJ, FrithCD, CarneyMWP, PriceJS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.Lancet1978; 9: 848–51.
AndreasenNC. Positive vs. negative schizophrenia: a critical evaluation.Schizophrenia Bull1985; 11: 380–9.
15.
LuchinsDJ, WeinberegerDR, WyattRJ. Schizophrenia: evidence for a subgroup with reversed cerebral asymmetry.Arch Gen Psychiatry1979; 36: 1309–11.
16.
DepueRA, DubickiME. Hospitalization and premorbid characteristics in withdrawn and active schizophrenics.J Cons Clin Psychol1974; 42: 628–38.
17.
MirskyAF. Neuropsychological bases of schizophrenia.Ann Rev Psychol1979: 20: 321–48.
18.
KetySS. The syndrome of schizophrenia: unresolved questions and opportunities for research.Br J Psychiatry1980; 136: 421–36.
19.
HecaenH, AlbertML. Disorders of mental functioning related to frontal lobe pathology. In: BennsonDF, BlumerD, eds. Psychiatric aspects of neurologic disease.New York: Grune & Stratum, 1975: 153–72.
20.
GoldenCJ, GraberB, CoffmanJ, BergRA, NewlinDB, BlochS. Structural brain defects in schizophrenia: identification by computed tomographic scan density measurements.Arch Gen Psychiatry1981; 38: 1014–7.
21.
GoldsteinG. Cognitive and perceptual differences between schizophrenics and organics.Schizophrenia Bull1978; 4: 160–85.
22.
BuchsbaumMA. Psychophysiology and schizophrenia.Schizophrenia Bull1977; 3: 7–14.
23.
IngvarDH. Functional landscapes of the dominant hemisphere.Brain Res1976; 107: 181–97.
24.
MccreadieKG, MacdonaldIM. High dosage haloperidol in chronic schizophrenia.Br J Psychiatry1977; 131: 310–6.
25.
HollisterLE, KimDY. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.Am J Psychiatry1982; 139: 1466–8.
26.
KimDY, HollisterLE. Thiothixene in the intensive treatment of drug-refractory chronic schizophrenics: doses and plasma concentrations. Scientific exhibit, 34th American Psychiatric Association Institute on Hospital and Community Psychiatry, Louisville, KY, October 1982.
27.
DonlonPT, HopkinJT, TupinJP, WicksJJ, WahbaM, MeadowA. Haloperidol for acute schizophrenic patients: an evaluation of three oral regimens.Arch Gen Psychiatry1980; 37: 691–5.
28.
NeborskyR, JanowskyD, MunsonE, DepryD. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol.Arch Gen Psychiatry1981; 38: 195–9.
TegelerVJ, LehmannE, QuadbeckH. Experimenteller Vergleich niedriger und hoher Haloperidol-Dosen in der Behandlung akut schizophrener Patienten.Arzneimiettelfors-chung1982; 32: 887–8.
31.
EscobarJI, BarronA, KiriakosR. A controlled study of neuroleptization with fluphenazine hydrochloride injections.J Clin Psychopharmacol1983; 3: 359–62.
32.
DonlonPT, HopkinJ, TupíNJP. Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol.Am J Psychiatry1979; 136: 273–8.
33.
TupinJP. Focal neuroleptization: an approach to optimal dosing for initial and continuing therapy.J Clin Psychopharmacol1985; 5(suppl): 155–215.
34.
SimpsonGM, PiEH. The treatment of refractory schizophrenia.Recent Adv Neuropsycho-pharmacol1981; 31: 393–8.
35.
SimpsonGM, YadalamK. Blood levels of neuroleptics: state of the art.J Clin Psychiatry1985; 46: 22–8.
PeetM, MiddlemissDN, YatesRA. Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine.Br J Psychiatry1981; 138: 112–7.
38.
WolkowitzDM, PickarD, DoranAR, BreierA, TarellJ, PaulSM. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.Am J Psychiatry1986; 143: 85–7.
39.
BrizerDA, HartmanN, SweeneyJ, MillmanRB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia.Am J Psychiatry1985; 142: 1106–7.
KolakowskaT., WilliamsA, ArdernM. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.Br J Psychiatry1985; 146: 229–46.
42.
StephensJ. Long term prognosis and followup in schizophrenia.Schizophrenia Bull1978; 4: 25–47.
43.
PostRM, RubinowDR, UhdeTW. Dopaminergic effects of carbamazepine.Arch Gen Psychiatry1986; 43: 392–5.
44.
FastDK, JonesBD, KusalicM, EricksonM. Effect of carbamazepine on neuroleptic plasma levels and efficacy.Am J Psychiatry1986; 143: 117–8.
45.
JannMW, EreshefskyL, SakladSR. Effects of carbamazepine on plasma haloperidol levels.J Clin Psychopharmacol1985; 5: 106–9.
46.
StevensJR, BigelowL, DenneyD. Telemetered EEG-EOG during psychotic behaviors of schizophrenia.Arch Gen Psychiatry1979; 36: 251–69.
47.
PostRM. Carbamazepine's acute and prophylactic effects in mania and depressive illness: an update.Int Drug Ther News1982; 17: 5–9.
